Digestive System Diseases

633 trials 301 recruiting

Filter these 633 trials by phase, country and sponsor.

Open in Search →

Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended

2024-516299-13-00 Resectable Gastric Cancer 4 2024-09-06
PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease. Ended

2024-512992-11-00 Crohn's disease 3 2024-08-30
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal car… Ended

2024-516005-23-00 metastatic squamous cell anal carcinoma 4 2024-08-22
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30
PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advance… Ended

2024-513515-27-00 stomach cancer stage IV with metastases 4 2024-07-10
PASSPORT Ended

2023-508584-72-00 Immune Bowel Disease (including Crohn's disease and Ulc 5 2024-07-10
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig… Ended

2023-508356-19-00 Pancreatic adenocarcinoma metastatic 4 2024-06-25
A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokin… Ended

2023-509226-21-00 Moderately to severely active ulcerative colitis 3 2024-06-13
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory col… Ended

2023-509771-17-00 Metastatic Colorectal cancer (mCRC) 10 2024-06-04
A Single Dose, Two – stage, Fasting State, Bioequivalence Study of Rifaximin 200 mg, film-coated tablets (Antibiotice S.A.) vs. Normix® 200 … Ended

2024-510671-38-00 healthy subjects 2 2024-05-26
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 4 2024-05-16
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
A study to investigate the safety, tolerability, and pharmacokinetics of Ent001 in patients with moderately to severely active ulcerative co… Ended

2023-507340-36-00 Inflammatory bowel disease (moderate to severe active u 3 2024-04-22
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended

2023-506893-11-00 Cirrhosis of the liver is a condition in which the live 4 2024-04-19
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metast… Ended

2023-505257-40-00 metastatic esophagogastric adenocarcinoma (Stage IV) 9 2024-04-17
Unravelling intestinal fibrosis in ulcerative colitis: INTERACT study Ended

2023-507907-73-00 Ulcerative colitis 11 2024-04-03
Evaluation of the bioavailability of two products containing esomeprazole under fasting and fed conditions: Esomeprazole-Syrup 40 mg dose (T… Ended

2023-506701-18-00 No therapeutic indication in the current trial with hea 3 2024-03-27
Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and… Ended

2024-519269-23-00 Crohn's disease 5 2024-03-27
A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healt… Ended

2023-505026-34-00 Cardiometabolic diseases 1 2024-03-26
Investigating the safety, feasibility, and optimal dose of Adalimumab-680LT in IBD – GUIDE study Ended

2023-508391-11-00 Inflammatory Bowel Disease (IBD) 7 2024-03-21
A Phase 1b Study to Characterize the Safety and Tolerability of TEV-53408 in Adults with Celiac Disease Ended

2022-502817-27-00 Celiac disease 3 2024-03-15
A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder… Ended

2022-502183-20-00 Moderately to Severely Active Ulcerative Colitis 5 2024-02-26
MK-7480 Multiple Ascending Dose Study in Healthy Participants Ended

2023-508982-34-00 Non-alcoholic steatohepatitis 3 2024-02-09
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants Ended

2023-504460-41-00 Fibrostenotic Crohn’s disease 3 2024-01-30